



Adempas[®] (riociguat) – New Contraindication

- On January 17, 2017, the [FDA approved](#) new information to the *Contraindications* section of the [Adempas \(riociguat\)](#) drug label pertaining to pulmonary hypertension associated with idiopathic interstitial pneumonias.
- Adempas is indicated for the treatment of adults with persistent/ recurrent chronic thromboembolic pulmonary hypertension (CTEPH), (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class and for the treatment of pulmonary arterial hypertension, (WHO Group 1), to improve exercise capacity, WHO functional class and to delay clinical worsening.
- In addition, the *Contraindications* and *Drug Interactions* sections pertaining to use with PDE inhibitors were updated with new information: do not administer within 24 hours of sildenafil ([Revatio[®]](#), [Viagra[®]](#)). Do not administer 24 hours before or within 48 hours after tadalafil ([Adcirca[®]](#), [Cialis[®]](#)).
- The *Dosage and Administration* part of the drug label was updated with the section, Transitioning to and from Adempas:
 - Discontinue sildenafil at least 24 hours prior to administering Adempas.
 - Discontinue tadalafil at least 48 hours prior to administering Adempas.
 - Discontinue Adempas at least 24 hours prior to administering a PDE5-inhibitor.
- Similar updates were made to the Medication Guide.
- Adempas carries a boxed warning for embryo-fetal toxicity.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.